Meropol NJ - Search Results

1

Implementing an Electronic End-of-Life Chemotherapy Utilization Measure.

Kraut J, Mooney K, Sweetenham JW, Page RD, Adelson K, Agarwala V, Fessele KL, Hamrick HJ, Kaganman I, Martineau J, Abernethy AP, Meropol NJ. Kraut J, et al. Among authors: meropol nj. J Oncol Pract. 2019 Apr;15(4):220-223. doi: 10.1200/JOP.18.00408. Epub 2019 Mar 18. J Oncol Pract. 2019. PMID: 30883256 No abstract available.

2

Opportunities for using big data to advance cancer care.

Meropol NJ. Meropol NJ. Clin Adv Hematol Oncol. 2018 Dec;16(12):807-809. Clin Adv Hematol Oncol. 2018. PMID: 30843889 No abstract available.

3

Prognostic Significance of Patient-Reported Outcomes in Cancer.

Kerrigan K, Patel SB, Haaland B, Ose D, Weinberg Chalmers A, Haydell T, Meropol NJ, Akerley W. Kerrigan K, et al. Among authors: meropol nj. JCO Oncol Pract. 2020 Apr;16(4):e313-e323. doi: 10.1200/JOP.19.00329. Epub 2020 Jan 9. JCO Oncol Pract. 2020. PMID: 32048943 Free PMC article.

4

American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants.

Hensley ML, Hagerty KL, Kewalramani T, Green DM, Meropol NJ, Wasserman TH, Cohen GI, Emami B, Gradishar WJ, Mitchell RB, Thigpen JT, Trotti A 3rd, von Hoff D, Schuchter LM. Hensley ML, et al. Among authors: meropol nj. J Clin Oncol. 2009 Jan 1;27(1):127-45. doi: 10.1200/JCO.2008.17.2627. Epub 2008 Nov 17. J Clin Oncol. 2009. PMID: 19018081

5

Impact of quality of life on patient expectations regarding phase I clinical trials.

Cheng JD, Hitt J, Koczwara B, Schulman KA, Burnett CB, Gaskin DJ, Rowland JH, Meropol NJ. Cheng JD, et al. Among authors: meropol nj. J Clin Oncol. 2000 Jan;18(2):421-8. doi: 10.1200/JCO.2000.18.2.421. J Clin Oncol. 2000. PMID: 10637258

6

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

Saltz LB, Meropol NJ, Loehrer PJ Sr, Needle MN, Kopit J, Mayer RJ. Saltz LB, et al. Among authors: meropol nj. J Clin Oncol. 2004 Apr 1;22(7):1201-8. doi: 10.1200/JCO.2004.10.182. Epub 2004 Mar 1. J Clin Oncol. 2004. PMID: 14993230 Clinical Trial.

7

Validation of diagnosis codes to identify side of colon in an electronic health record registry.

Luhn P, Kuk D, Carrigan G, Nussbaum N, Sorg R, Rohrer R, Tucker MG, Arnieri B, Taylor MD, Meropol NJ. Luhn P, et al. Among authors: meropol nj. BMC Med Res Methodol. 2019 Aug 19;19(1):177. doi: 10.1186/s12874-019-0824-7. BMC Med Res Methodol. 2019. PMID: 31426736 Free PMC article.

8

Octreotide does not prevent diarrhea in patients treated with weekly 5-fluorouracil plus high-dose leucovorin.

Meropol NJ, Blumenson LE, Creaven PJ. Meropol NJ, et al. Am J Clin Oncol. 1998 Apr;21(2):135-8. doi: 10.1097/00000421-199804000-00007. Am J Clin Oncol. 1998. PMID: 9537197 Clinical Trial.

9

Patient-physician discordance in goals of care for patients with advanced cancer.

Douglas SL, Daly BJ, Meropol NJ, Lipson AR. Douglas SL, et al. Among authors: meropol nj. Curr Oncol. 2019 Dec;26(6):370-379. doi: 10.3747/co.26.5431. Epub 2019 Dec 1. Curr Oncol. 2019. PMID: 31896935 Free PMC article.

10

Carcinoembryonic Antigen-Still More to Learn From the Real World.

Miksad RA, Meropol NJ. Miksad RA, et al. Among authors: meropol nj. JAMA Oncol. 2018 Mar 1;4(3):315-316. doi: 10.1001/jamaoncol.2017.4408. JAMA Oncol. 2018. PMID: 29270625 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

290 results

Search Page